About: Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on August 2010

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2010 (ast) наукова стаття, опублікована в серпні 2010 (uk) مقالة علمية نشرت في أغسطس 2010 (ar) scientific article published on August 2010 (en)
publication date	wds:Q37442881-7F44170C-9142-463B-AB2F-AC9B268B9BC2
publication date	2010-08-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37442881-64C163FC-8CE9-4A6B-9032-04942EA89222
language of work or name	English
cites work	wds:Q37442881-0EC36D34-09D5-4F0D-A0A5-A7B2B9C8FC9C wds:Q37442881-2E927ABC-9D89-448B-80CF-48694CAC6004 wds:Q37442881-356A1B02-3925-4761-B6CB-301D6F09242F wds:Q37442881-5B767569-0AC5-4A3E-B869-819C61BE86D0 wds:Q37442881-66302628-F25F-49E2-A29D-BC7A84D97FD9 wds:Q37442881-78269020-444A-4079-8CA9-EBF728565A11 wds:Q37442881-7DEBAAF4-D681-47FF-BF33-BAAC23A1465B wds:Q37442881-7ED1D0DD-A251-4518-9240-15B2BF5B938E wds:Q37442881-7FE97300-76A7-4D01-B8C8-F67593D2D7E3 wds:Q37442881-9BC4C5B9-8DD6-49ED-BDE9-9757EACCEB62 wds:Q37442881-AB57A577-6722-4440-A189-4C3BB01C5BED wds:Q37442881-AB763899-036D-4795-B9C5-1D627A1EB606 wds:Q37442881-ABEF10E7-F68B-4231-8C30-9EB95B74DA98 wds:Q37442881-AC0D6963-AD4D-4978-BB49-6CBB45DE59C6 wds:Q37442881-B0940D03-E063-486E-BE1E-82A2C29F9953 wds:Q37442881-BF70D29D-87D3-44A5-9690-6294D8703F06 wds:Q37442881-CAF8550B-71E9-47C3-B2C1-A15913A6E132 wds:Q37442881-E7464477-D714-43A0-A1A3-FE86FD96D5A5 wds:Q37442881-E83A036C-9162-490E-8735-1B2359CF73FB wds:Q37442881-FC35973E-374C-4CD0-A43B-7A5D36893ADD
cites work	Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
author name string	wds:Q37442881-063C95F1-1867-4D44-98F8-BFE679D36CE6 wds:Q37442881-15FC67C2-21F8-40C5-B11B-39A964D75927 wds:Q37442881-59AEFB4F-0A84-4A4D-B78D-FFF895282EFA wds:Q37442881-65C661DD-04E7-4954-8600-2B92C5220F1F wds:Q37442881-765F92B8-D5D5-4A96-BC74-749ED10E6762 wds:Q37442881-98D216DC-3FCA-4177-9D94-CA90DCCC3B51 wds:Q37442881-D9A86A43-EF04-4F80-AF7D-1454FAA3C892 wds:Q37442881-DC9E1CEF-EEA0-4B8F-BA6C-786B1AD864A7 wds:Q37442881-DECD0167-7486-4F80-AFC6-87529861B602 wds:Q37442881-DFD6E289-FAA5-45D5-8AD7-4DDDE63DA810 wds:Q37442881-E17FED6E-D304-4059-9FE7-A2525E0CFA70
author name string	Adam M Brufsky Maura Dickler Clifford A Hudis Mansoor Saleh Andrew D Seidman Alison K Conlin Diana Lake Alicia Clawson Tiffany Traina Michael Danso Ariadne Bach
rdfs:label	Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. (en) Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. (nl) Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. (ast)
skos:prefLabel	Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. (en) Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. (nl) Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. (ast)
name	Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. (en) Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. (nl) Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. (ast)
author	wds:Q37442881-A34884CF-9479-4498-9C06-3893D03E38BA
author	Gabriella D'Andrea-Carlino
title	wds:Q37442881-476FB5D4-078B-405B-98A7-D48C04387830
title	Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer (en)
page(s)	wds:Q37442881-379FBDD0-B7F4-4DAE-83DA-1C6FA4E96B06
page(s)	281-287
instance of	wds:Q37442881-D4ABA028-1278-4B8E-AC1E-01B423AD2F7C
instance of	scholarly article

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software